RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Royalty Pharma plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$60.27−0.69 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $33.56B
- P/E (TTM)
- 34.2
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
63.8%
367M of 575M shares
Institutional holders
643
106 new, 43 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
0 buys · 73 sales
Net sold $92.59M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 39,245,593 | 9.10% | 13G (passive) amendment | Mar 31, 2025 |
| Morgan Stanley | 38,907,011 | 9.20% | 13G (passive) amendment | Jun 30, 2025 |
| Capital International Investors | 37,772,419 | 8.80% | 13G (passive) amendment | Mar 31, 2026 |
| R & H Trust Co. (Guernsey) Limited | 29,926,170 | 6.90% | 13D (active) amendment | Apr 30, 2025 |
| Abigail P. Johnson | 27,900,714 | 6.50% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 25,445,414 | 5.70% | 13G (passive) | Dec 31, 2024 |
| Legorreta G. Pablo | 101,785,843 | 18.73% | 13D (active) amendment | Aug 13, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RPRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 42,931,597 | 7.47% | $2.41B | −640,036 | 0.13% |
| Capital International Investors | 35,273,770 | 6.13% | $1.98B | +268,034 | 0.41% |
| BlackRock, Inc. | 27,832,977 | 4.84% | $1.56B | +1,925,232 | 0.02% |
| FMR LLC | 24,513,814 | 4.26% | $1.37B | −638,428 | 0.06% |
| State Street Corp | 12,338,229 | 2.15% | $691.80M | +1,348,378 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 11,193,657 | 1.95% | $627.63K | +9,259,396 | 0.06% |
| Swedbank AB | 10,726,608 | 1.87% | $601.44M | −860,085 | 0.52% |
| Baillie Gifford & Co | 10,015,578 | 1.74% | $561.57M | −6,140,099 | 0.51% |
| Capital World Investors | 9,517,337 | 1.66% | $533.64M | +1,480,623 | 0.06% |
| Geode Capital Management, LLC | 8,058,048 | 1.40% | $450.58M | +188,416 | 0.02% |
| Caledonia (Private) Investments Pty Ltd | 5,775,851 | 1.00% | $323.85M | −1,392,548 | 11.06% |
| Norges Bank | 5,336,084 | 0.93% | $299.19M | New | 0.03% |
| Vanguard Capital Management LLC | 4,826,617 | 0.84% | $270.63M | +294,731 | 0.01% |
| Northern Trust Corp | 4,718,859 | 0.82% | $264.59M | +910,124 | 0.03% |
| Royal London Asset Management Ltd | 4,319,595 | 0.75% | $242.20M | +511,242 | 0.45% |
| Aqr Capital Management LLC | 4,305,412 | 0.75% | $241.40M | +523,374 | 0.08% |
| Invesco Ltd. | 4,232,577 | 0.74% | $237.32M | +480,178 | 0.02% |
| Bank Of America Corp /De/ | 4,149,422 | 0.72% | $232.66M | +653,576 | 0.01% |
| Legal & General Group Plc | 3,800,504 | 0.66% | $213.09M | +437,632 | 0.04% |
| Amundi | 3,723,864 | 0.65% | $208.80M | +635,091 | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 643 | 367M | 63.8% | 106 / 291 | 177 / 43 | 45M | 33M |
| Q1 2026 | 591 | 355M | 61.7% | 117 / 225 | 181 / 59 | 52M | 43M |
| Q4 2025 | 539 | 358M | 62.2% | 108 / 235 | 136 / 51 | 46M | 19M |
| Q3 2025 | 488 | 331M | 57.5% | 92 / 206 | 132 / 52 | 47M | 59M |
| Q2 2025 | 455 | 343M | 59.7% | 77 / 172 | 156 / 64 | 66M | 34M |
| Q1 2025 | 446 | 311M | 54.0% | 85 / 159 | 148 / 50 | 40M | 39M |
| Q4 2024 | 416 | 322M | 56.0% | 77 / 161 | 136 / 50 | 33M | 24M |
| Q3 2024 | 395 | 314M | 54.7% | 60 / 159 | 122 / 39 | 43M | 30M |
| Q2 2024 | 378 | 325M | 56.5% | 59 / 141 | 128 / 56 | 27M | 110M |
| Q1 2024 | 379 | 410M | 71.2% | 65 / 163 | 112 / 47 | 68M | 24M |
| Q4 2023 | 363 | 366M | 63.7% | 79 / 148 | 109 / 29 | 85M | 19M |
| Q3 2023 | 313 | 300M | 52.1% | 35 / 137 | 115 / 47 | 17M | 36M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of RPRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| New Perspective Fund | 19,645,749 | 3.42% | $1.10B | 0.65% | Jun 30, 2026 |
| Capital Income Builder | 7,427,586 | 1.29% | $433.99M | 0.33% | Jul 31, 2026 |
| Growth Fund of America | 6,412,195 | 1.12% | $357.54M | 0.10% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 4,471,210 | 0.78% | $250.70M | 0.26% | Jun 30, 2026 |
| Patient Opportunity Trust | 2,500,000 | 0.43% | $140.18M | 6.98% | Jun 30, 2026 |
| VictoryShares Free Cash Flow ETF | 2,438,172 | 0.42% | $136.71M | 1.76% | Jun 30, 2026 |
| Invesco Discovery Mid Cap Growth Fund | 1,707,479 | 0.30% | $99.77M | 1.47% | Jul 31, 2026 |
| Vanguard High Dividend Yield Index Fund | 1,665,008 | 0.29% | $97.29M | 0.10% | Jul 31, 2026 |
| Growth Fund | 1,658,815 | 0.29% | $93.01M | 0.16% | Jun 30, 2026 |
| iShares Russell 1000 Value ETF | 925,878 | 0.16% | $51.91M | 0.07% | Jun 30, 2026 |
| Vanguard Global Equity Fund | 924,999 | 0.16% | $51.86M | 0.68% | Jun 30, 2026 |
| iShares U.S. Pharmaceuticals ETF | 880,087 | 0.15% | $49.35M | 4.33% | Jun 30, 2026 |
| Eventide Dividend Opportunities Fund | 774,108 | 0.13% | $43.40M | 3.05% | Jun 30, 2026 |
| iShares MSCI USA Momentum Factor ETF | 653,937 | 0.11% | $38.21M | 0.15% | Jul 31, 2026 |
| ALPS | OShares U.S. Small-Cap Quality Dividend ETF | 482,094 | 0.08% | $26.88M | 3.07% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pablo G. Legorreta | CEO, Chairman of the Board, Director | 27,968,937 | 4.86% | Aug 7, 2026 |
| Marshall Urist | EVP, Research & Investments | 1,379,674 | 0.24% | Sep 30, 2026 |
| Christopher Hite | EVP & Chairman, Partnering | 1,532,390 | 0.27% | Sep 24, 2026 |
| Terrance P. Coyne | EVP & CFO | 1,839,167 | 0.32% | Aug 17, 2026 |
| Arthur Richard McGivern | EVP, Investments & GC | – | – | Jan 6, 2026 |
| George W. Lloyd | EVP, Investments & CLO | 2,724,616 | 0.47% | Dec 19, 2025 |
| Bonnie L. Bassler | Director | 79,823 | 0.01% | Sep 30, 2026 |
| David C. Hodgson | Director | 37,873 | 0.01% | Jun 8, 2026 |
| Elizabeth H. Weatherman | Director | 13,103 | 0.00% | Jun 8, 2026 |
| Vlad Coric | Director | 15,343 | 0.00% | Jun 8, 2026 |
| Ted W. Love | Director | 58,393 | 0.01% | Jun 8, 2026 |
| Gregory Norden | Director | 196,348 | 0.03% | Jun 8, 2026 |
| Carole Ho | Director | 13,103 | 0.00% | Jun 8, 2026 |
| Catherine M. Engelbert | Director | 55,673 | 0.01% | Jun 8, 2026 |
| Henry A. Fernandez | Director | 123,524 | 0.02% | Jun 30, 2025 |
| Errol B. Desouza | Director | 81,352 | 0.01% | May 14, 2025 |
| Pharma plc Royalty | Director | – | – | Apr 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bonnie L. Bassler Director | Sep 30, 2026 | Award | +642 | $58.41 | $37.50K | 79,823 |
| Marshall Urist EVP, Research & Investments | Sep 28, 2026 | Sale(10b5-1 plan) | −4,126 | $57.88 | $238.81K | 4,126 |
| Christopher Hite EVP & Chairman, Partnering | Sep 22, 2026 | Sale(10b5-1 plan) | −3,927 | $58.93 | $231.42K | 270,401 |
| Christopher Hite EVP & Chairman, Partnering | Sep 22, 2026 | Sale(10b5-1 plan) | −96,073 | $58.51 | $5.62M | 274,328 |
| Christopher Hite EVP & Chairman, Partnering | Aug 19, 2026 | Gift | −16,800 | – | – | 23,200 |
| Christopher Hite EVP & Chairman, Partnering | Aug 18, 2026 | Sale(10b5-1 plan) | −100,000 | $59.97 | $6.00M | 370,401 |
| Terrance P. Coyne EVP & CFO | Aug 13, 2026 | Sale(10b5-1 plan) | −1,772 | $59.14 | $104.80K | 0 |
| Terrance P. Coyne EVP & CFO | Aug 13, 2026 | Sale(10b5-1 plan) | −9,230 | $58.59 | $540.79K | 1,772 |
| Christopher Hite EVP & Chairman, Partnering | Aug 5, 2026 | Award | +11,002 | – | – | 470,401 |
| Pablo G. Legorreta CEO, Chairman of the Board, Director | Aug 5, 2026 | Award | +65,216 | – | – | 1,307,820 |
| Marshall Urist EVP, Research & Investments | Aug 5, 2026 | Award | +8,252 | – | – | 8,252 |
| Terrance P. Coyne EVP & CFO | Aug 5, 2026 | Award | +11,002 | – | – | 11,002 |
| Marshall Urist EVP, Research & Investments | Jul 1, 2026 | Sale(10b5-1 plan) | −9,099 | $55.88 | $508.45K | 0 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −29,400 | $56.44 | $1.66M | 40,600 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −600 | $57.09 | $34.25K | 40,000 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −97,446 | $56.50 | $5.51M | 461,953 |
| Christopher Hite EVP & Chairman, Partnering | Jun 30, 2026 | Sale(10b5-1 plan) | −2,554 | $57.10 | $145.83K | 459,399 |
| Bonnie L. Bassler Director | Jun 30, 2026 | Award | +689 | $54.40 | $37.48K | 79,181 |
| Marshall Urist EVP, Research & Investments | Jun 24, 2026 | Sale(10b5-1 plan) | −9,098 | $55.18 | $502.03K | 9,099 |
| Christopher Hite EVP & Chairman, Partnering | Jun 23, 2026 | Sale(10b5-1 plan) | −32,408 | $54.11 | $1.75M | 676,991 |
| Christopher Hite EVP & Chairman, Partnering | Jun 23, 2026 | Sale(10b5-1 plan) | −117,592 | $54.47 | $6.41M | 559,399 |
| Bonnie L. Bassler Director | Jun 5, 2026 | Award | +4,545 | – | – | 78,492 |
| Gregory Norden Director | Jun 5, 2026 | Award | +4,545 | – | – | 196,348 |
| Carole Ho Director | Jun 5, 2026 | Award | +4,545 | – | – | 4,545 |
| Ted W. Love Director | Jun 5, 2026 | Award | +4,545 | – | – | 58,393 |
| David C. Hodgson Director | Jun 5, 2026 | Award | +4,545 | – | – | 37,873 |
| Catherine M. Engelbert Director | Jun 5, 2026 | Award | +4,545 | – | – | 55,673 |
| Vlad Coric Director | Jun 5, 2026 | Award | +4,545 | – | – | 15,343 |
| Elizabeth H. Weatherman Director | Jun 5, 2026 | Award | +4,545 | – | – | 13,103 |
| Terrance P. Coyne EVP & CFO | May 26, 2026 | Sale(10b5-1 plan) | −64,399 | $53.98 | $3.48M | 0 |
| Marshall Urist EVP, Research & Investments | May 20, 2026 | Sale(10b5-1 plan) | −13,684 | $52.75 | $721.83K | 18,197 |
| Gregory Norden Director | May 14, 2026 | Sale(10b5-1 plan) | −3,045 | $53.00 | $161.39K | 191,803 |
| Marshall Urist EVP, Research & Investments | May 14, 2026 | Sale(10b5-1 plan) | −13,684 | $53.06 | $726.07K | 31,881 |
| Marshall Urist EVP, Research & Investments | May 6, 2026 | Award | +18,197 | – | – | 45,565 |
| Terrance P. Coyne EVP & CFO | May 6, 2026 | Award | +24,263 | – | – | 64,399 |
| Christopher Hite EVP & Vice Chairman | May 6, 2026 | Award | +24,263 | – | – | 709,399 |
| Pablo G. Legorreta CEO, Chairman of the Board, Director | May 6, 2026 | Award | +143,821 | – | – | 1,242,604 |
| Terrance P. Coyne EVP & CFO | Apr 28, 2026 | Sale(10b5-1 plan) | −32,916 | $49.78 | $1.64M | 0 |
| Terrance P. Coyne EVP & CFO | Apr 28, 2026 | Sale(10b5-1 plan) | −1,875 | $49.78 | $93.34K | 40,136 |
| Terrance P. Coyne EVP & CFO | Apr 1, 2026 | Sale(10b5-1 plan) | −1,875 | $48.33 | $90.62K | 42,011 |
| Terrance P. Coyne EVP & CFO | Apr 1, 2026 | Sale(10b5-1 plan) | −32,916 | $48.33 | $1.59M | 32,916 |
| Bonnie L. Bassler Director | Mar 31, 2026 | Award | +815 | $45.98 | $37.47K | 73,947 |
| Terrance P. Coyne EVP & CFO | Mar 23, 2026 | Sale(10b5-1 plan) | −1,875 | $45.53 | $85.37K | 43,886 |
| Terrance P. Coyne EVP & CFO | Mar 23, 2026 | Sale(10b5-1 plan) | −32,916 | $45.53 | $1.50M | 65,832 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −583 | $47.01 | $27.41K | 45,761 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −22,487 | $46.67 | $1.05M | 109,177 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −10,429 | $47.01 | $490.27K | 98,748 |
| Terrance P. Coyne EVP & CFO | Mar 2, 2026 | Sale(10b5-1 plan) | −1,292 | $46.67 | $60.30K | 46,344 |
| Terrance P. Coyne EVP & CFO | Feb 23, 2026 | Sale(10b5-1 plan) | −1,875 | $45.32 | $84.98K | 47,636 |
| Terrance P. Coyne EVP & CFO | Feb 23, 2026 | Sale(10b5-1 plan) | −32,916 | $45.32 | $1.49M | 131,664 |
| Marshall Urist EVP, Research & Investments | Feb 11, 2026 | Award | +19,970 | – | – | 27,368 |
| Christopher Hite EVP & Vice Chairman | Feb 11, 2026 | Award | +26,626 | – | – | 685,136 |
| Pablo G. Legorreta CEO, Chairman of the Board, Director | Feb 11, 2026 | Award | +157,828 | – | – | 1,098,783 |
| Terrance P. Coyne EVP & CFO | Feb 11, 2026 | Award | +26,626 | – | – | 49,511 |
| Terrance P. Coyne EVP & CFO | Feb 4, 2026 | Sale(10b5-1 plan) | −19,076 | $43.29 | $825.80K | 164,580 |
| Terrance P. Coyne EVP & CFO | Feb 4, 2026 | Sale(10b5-1 plan) | −1,087 | $43.29 | $47.06K | 22,885 |
| Terrance P. Coyne EVP & CFO | Feb 3, 2026 | Sale(10b5-1 plan) | −108,759 | $42.84 | $4.66M | 183,656 |
| Terrance P. Coyne EVP & CFO | Feb 3, 2026 | Sale(10b5-1 plan) | −6,195 | $42.84 | $265.39K | 23,972 |
| Terrance P. Coyne EVP & CFO | Feb 2, 2026 | Sale(10b5-1 plan) | −102,581 | $42.08 | $4.32M | 292,415 |
| Terrance P. Coyne EVP & CFO | Feb 2, 2026 | Sale(10b5-1 plan) | −5,843 | $42.08 | $245.87K | 30,167 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Marshall Urist Officer | Oct 5, 2026 | 4,126 | $235.59K | Oct 5, 2026 | Equity Performance Award |
| Marshall Urist Officer | Sep 28, 2026 | 4,126 | $238.81K | Sep 28, 2026 | Equity Performance Award |
| Investment Partners LLC SCH Officer | Sep 22, 2026 | 100,000 | $5.85M | Sep 22, 2026 | Acquired from issuer in private transaction |
| Investment Partners LLC SCH Officer | Aug 18, 2026 | 100,000 | $6.01M | Aug 18, 2026 | Acquired from issuer in private transaction |
| Coyne Terrance Officer | Aug 13, 2026 | 11,002 | $644.28K | Aug 13, 2026 | Acquired as compensation -- Performance Awards |
| B. De Souza Errol Former Affiliate | Aug 12, 2026 | 206,352 | $11.93M | Aug 12, 2026 | Conversion of LP Interests |
| B. De Souza Errol Former Affiliate | Aug 12, 2026 | 125,000 | $7.22M | Aug 12, 2026 | Conversion of LP Interests |
| Marshall Urist Officer | Jul 1, 2026 | 9,099 | $508.45K | Jul 1, 2026 | Equity Performance Award |
| Investment Partners LLC SCH Officer | Jul 1, 2026 | 100,000 | $5.71M | Jun 30, 2026 | Acquired from issuer in private transaction |
| Marshall Urist Officer | Jun 24, 2026 | 9,098 | $502.07K | Jun 24, 2026 | Equity Performance Award |
| Investment Partners LLC SCH Officer | Jun 23, 2026 | 150,000 | $8.17M | Jun 23, 2026 | Acquired from issuer in private transaction |
| Hite Christopher Officer | Jun 23, 2026 | 30,000 | $1.66M | Jun 23, 2026 | Purchase in IPO - Reserved Shares Program |
| Coyne Terrance Officer | May 26, 2026 | 64,399 | $3.47M | May 26, 2026 | Acquired as compensation -- Performance Awards |
| Marshall Urist Officer | May 20, 2026 | 13,684 | $721.84K | May 20, 2026 | Equity Performance Award |
| Marshall Urist Officer | May 14, 2026 | 13,684 | $726.14K | May 14, 2026 | Equity Performance Award |